Trial reportPsychiatry research2015
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion.
Trial report in Psychiatry research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.The international journal of neuropsychopharmacology · 2015Pooled it
- Attentional control may be modifiable with Mindfulness-Based Cognitive Therapy to Prevent Suicide.Behaviour research and therapy · 2021Trial
- Working memory associated with anti-suicidal ideation effect of repeated-dose intravenous ketamine in depressed patients.European archives of psychiatry and clinical neuroscience · 2021Trial
- The Comparative Efficacy of Antidepressant and Psychological Therapies on Cognition in Depression: A Systematic Review and Network Meta-Analysis.Neuropsychology review · 2025Review
- Alpha oscillatory dysregulation: mapping EEG oscillatory in suicidal depression.Frontiers in human neuroscience · 2025Article
- Standardized Treatment and Shortened Depression Course can Reduce Cognitive Impairment in Adolescents With Depression.Journal of the Korean Academy of Child and Adolescent Psychiatry · 2024Article
- Pharmacologic Approaches to Suicide Prevention.Focus (American Psychiatric Publishing) · 2023Review
- Cognitive effort avoidance in veterans with suicide attempt histories.Acta psychologica · 2022Article
- Computerized Working Memory Training in Remission From Major Depressive Disorder: Effects on Emotional Working Memory, Processing Speed, Executive Functions, and Associations With Symptoms.Frontiers in behavioral neuroscience · 2022Article
- The Influence of Family-Related Factors on Suicide in Major Depression Patients.Frontiers in psychiatry · 2022Article
- Educational attainment reduces the risk of suicide attempt among individuals with and without psychiatric disorders independent of cognition: a bidirectional and multivariable Mendelian randomization study with more than 815,000 participants.Translational psychiatry · 2020Article
- Understanding the Complex of Suicide in Depression: from Research to Clinics.Psychiatry investigation · 2020Article
- Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.Frontiers in psychiatry · 2019Review
- Association between cognitive deficits and suicidal ideation in patients with major depressive disorder.Scientific reports · 2017Article
- Sleep architecture parameters as a putative biomarker of suicidal ideation in treatment-resistant depression.Journal of affective disorders · 2017Article
- Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management.Focus (American Psychiatric Publishing) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Neuropsychological dysfunction is associated with risk for suicidal behavior, but it is unknown if antidepressant medication treatment is effective in reducing this dysfunction, or if specific medications might be more beneficial. A comprehensive neuropsychological battery was administered at baseline and after 8 weeks of treatment within a randomized, double-blind clinical trial comparing paroxetine and bupropion in patients with DSM-IV Major Depressive Disorder and either past suicide attempt or current suicidal thoughts. Change in neurocognitive performance was compared between assessments and between medication groups. Treatment effects on the Hamilton Depression Rating Scale and Scale for Suicide Ideation were compared with neurocognitive improvement. Neurocognitive functioning improved after treatment in all patients, without clear advantage for either medication. Improvement in memory performance was associated with a reduction in suicidal ideation independent of the improvement of depression severity. Overall, antidepressant medication improved neurocognitive performance in patients with major depression and suicide risk. Reduced suicidal ideation was best predicted by a combination of the independent improvements in both depression symptomatology and verbal memory. Targeted treatment of neurocognitive dysfunction in these patients may augment standard medication treatment for reducing suicidal behavior risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.